It will be hard to forecast a run rate at this early stage of the transition. All they know at this point is the strategy appears to be working, ebitda will be better than last year, revenue will be lower but margins higher.
The really good take away is the retention of one of their key IP holders until 2020. I work in the tech sector and experts in the digital domain are very hot property both here and OS. Signing on for another 3 years is a big vote of confidence in the business strategy.
- Forums
- ASX - By Stock
- IMS
- Ann: Market Update
Ann: Market Update, page-5
Featured News
Add IMS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online